Table 1. Clinical characteristics according to WSE in NSCLC patients.
| ALL (N=42) | WSE (-) | WSE (+) | p-Value | ||
|---|---|---|---|---|---|
| (N=23) | (N=19) | ||||
| % (n/N) | % (n/N) | % (n/N) | |||
| Gender | Female | 71.4(30/42) | 43.3 (13/30) | 56.7 (17/30) | |
| Male | 28.6 (12/42) | 83.3 (10/12) | 16.7 (2/12) | 0.037 | |
| Age | Median (Range) | 67(36-82) | 67(36-82) | 66(37-77) | 0.552 |
| < 60 years | 31 (13/42) | 53.8 (7/13) | 46.2 (6/13) | ||
| ≥ 60 years | 69.0 (29/42) | 55.2 (16/29) | 44.8 (13/29) | 1 | |
| WSE Index | WSE index Median (Range) | 72 (64.4-249.6) | NA | 72 (64.4-249.6) | |
| Tobacco-Smoking Exposure | Smoking index Median (Range) | 0 (0-55) | 3 (0-55) | 0 (0-0) | < 0.001 |
| Non-smoker | 61.9 (26/42) | 34.6 (9/26) | 65.4 (17/26) | ||
| Smoker | 38.1 (16/42) | 87.5 (14/16) | 12.5 (2/16) | 0.001 | |
| ECOG PS | 0-1 | 85.7 (36/42) | 58.3 (21/36) | 41.7 (15/36) | |
| 2+ | 14.3 (6/42) | 33.3 (2/6) | 66.7 (4/6) | 0.384 | |
| Predominant histological pattern | Lepidic | 14.3 (6/42) | 66.7 (4/6) | 33.3 (2/6) | 0.878 |
| Acinar | 33.3 (14/42) | 50.0 (7/14) | 50 (7/14) | ||
| Papillary | 7.1 (3/42) | 66.7 (2/3) | 33.3 (1/3) | ||
| Solid | 45.2 (19/42) | 52.6 (10/19) | 47.4 (9/19) | ||
| Histological Grade | Low | 45.2 (19/42) | 52.6 (10/19) | 47.4 (9/19) | 0.818 |
| Intermediate | 40.5 (17/42) | 52.9 (9/17)) | 47.1 (8/17) | ||
| High | 14.3 (6/42) | 66.7 (4/6) | 33.3 (2/6) | ||
| Disease Stage | IIIB | 21.4 (9/42) | 77.8 (7/9) | 22.2 (2/9) | |
| IV | 78.6 (33/42)) | 48.5 (16/33) | 51.5 (17/33) | 0.149 | |
| CNS Metastases | Absent | 69.7 (23/33) | 52.2 (12/23) | 47.8 (11/23) | |
| Present | 30.3 (10/33) | 40 (4/10) | 60 (6/10) | 0.708 | |
| Lung Metastases | Absent | 72.7 (24/33) | 45.8 (11/24) | 54.2 (13/24) | |
| Present | 27.3 (9/33) | 55.6 (5/9) | 44.4 (4/9) | 0.708 | |
| Liver Metastases | Absent | 90.9 (30/33) | 46.7 (14/30) | 53.3 (16/30) | |
| Present | 9.1 (3/33) | 66.7 (2/3) | 33.3 (1/3) | 0.601 | |
| Bone metastases | Absent | 72.7 (24/33) | 54.2 (13/24) | 45.8 (11/24) | |
| Present | 27.3 (9/33) | 33.3 (3/9) | 66.7 (6/9) | 0.438 | |
| CEA | <10 ng/mL | 41.5 (17/41) | 52.9 (9/17) | 47.1 (8/20) | |
| ≥10 ng/mL | 58.5 (24/41) | 54.2 (13/24) | 45.8 (11/24) | 1 |
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group Performance Status; CNS: Central Nervous System, CEA: Carcinoembryonic antigen, NA non-applicable